Article

Oral contraceptives and venous thromboembolism: a five-year national case-control study.

Herlev University Hospital, Herlev, Denmark.
Contraception (Impact Factor: 2.93). 03/2002; 65(3):187-96. DOI: 10.1016/S0010-7824(01)00307-9
Source: PubMed

ABSTRACT The objective of this study was to assess the influence of oral contraceptives (OCs) on the risk of venous thromboembolism (VTE) in young women. A 5-year case-control study including all Danish hospitals was conducted. All women 15-44 years old, suffering a first ever deep venous thrombosis or a first pulmonary embolism (PE) during the period January 1, 1994, to December 30, 1998, were included. Controls were selected annually, 600 per year in 1994-1995 and 1200 per year 1996-1998. Response rates for cases and controls were 87.2% and 89.7%, respectively. After exclusion of nonvalid diagnoses, pregnant women, and women with previous thrombotic disease, 987 cases and 4054 controls were available for analysis. A multivariate, matched analysis was performed. Controls were matched to cases within 1-year age bands. Adjustment was made for confounding influence (if any) from the following variables: age, year, body mass index, length of OC use, family history of VTE, cerebral thrombosis or myocardial infarction, coagulopathies, diabetes, years of schooling, and previous birth. The risk of VTE among current users of OCs was primarily influenced by duration of use, with significantly decreasing odds ratios (OR) over time: <1 year, 7.0 (5.1-9.6); 1-5 years, 3.6 (2.7-4.8); and >5 years, 3.1 (2.5-3.8), all compared with nonusers of OCs. After adjustment for confounders, current use of OCs with second- (levonorgestrel or norgestimate) and third- (desogestrel or gestodene) generation progestins when compared with nonuse resulted in ORs for VTE of 2.9 (2.2-3.8) and 4.0 (3.2-4.9), respectively. After adjusting for progestin types and length of use, the risk decreased significantly with decreasing estrogen dose. With 30-40 microg as reference, 20 and 50 microg products implied ORs of 0.6 (0.4-0.9) and 1.6 (0.9-2.8), respectively (p(trend) = 0.02). After correction for duration of use and differences in estrogen dose, the third/second-generation risk ratio was 1.3 (1.0-1.8; p <0.05). In conclusion, use of OCs was associated significantly to the risk of VTE. The risk among current users was reduced by more than 50% during the first years of use. The risk increased more than 100% with increasing estrogen dose, and the difference in risk between users of third- and second-generation OCs, after correction for length of use and estrogen dose, was 33%.

0 Bookmarks
 · 
69 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Die Lungenembolie ist ein häufiges Krankheitsbild. Ihre Mortalität be-trägt ca. 10 % und betrifft insbesondere die Akutphase. Immobilisation, operative Eingriffe, höheres Lebensalter, maligne Erkrankungen, hormonelle Faktoren sowie angeborene und erworbene Koagulopathien sind wichtige Risikofaktoren. Spiral-computertomographie und Ventilations-Perfusion-Szintigraphie sind die entschei-denden bildgebenden Verfahren. Als Goldstandard ist nach wie vor die Pulmonalis-angiographie zu betrachten. Durch die prophylaktische Gabe von unfraktionierten bzw. niedermolekularen Heparinen konnte das Risiko einer Lungenembolie um ca. 50 % gesenkt werden. Die Therapie der Lungenembolie orientiert sich am klini-schen Schweregrad und reicht von der ambulanten Behandlung mit niedermoleku-larem Heparin bis zur Durchführung der Thrombolyse bzw. Embolektomie bei mas-siver Lungenembolie. Die Dauer der Langzeit-Antikoagulation, in der Regel mit oralen Vitamin-K-Antagonisten, sollte sich am individuellen Risikoprofil des Pa-tienten orientieren. Die Lungenembolie ist ein häufiges Krankheitsbild und eine lebensbedrohliche Komplikation der tiefen Beinvenenthrombose. Auf den folgenden Seiten soll eben-so auf die entscheidenden Risikofaktoren wie auch auf die Besonderheiten der Dia-gnostik, Prävention und Therapie dieses Krankheitsbildes eingegangen werden. Wegen der engen kausalen Verknüpfung zwischen der tiefen Beinvenenthrombose und der Lungenembolie – was im angelsächsischen Sprachgebrauch mit dem Be-griff "venous thromboembolism" präziser ausgedrückt ist als im Deutschen – wer-den auch in diesem Artikel Daten diskutiert, die beide Aspekte des pathophysiolo-gischen Geschehens berücksichtigen.
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper reviews the risk of thrombosis with use of different types of hormonal contraception in women of different ages.
    Expert Opinion on Drug Safety 10/2014; 13(10):1353-60. · 2.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Increasing evidence suggests an association between diabetes and risk of venous thromboembolism (VTE); however, the results are inconsistent. We conducted a systematic review and meta-analysis of all epidemiological evidence to clarify association of diabetes with risk of VTE.Methods We searched MEDLINE and EMBASE to retrieve all relevant articles. Pooled effect estimates were calculated through a random-effects model.ResultsSixteen articles involving 803,627,121 participants and 10,429,227 VTE patients were included. Pooled analysis of all evidence suggested that diabetes was associated with increased risk of VTE (HR, 1.35; 95%CI, 1.17-1.55; p = 2.92*10- 5), with evidence of small-study effect (p = 0.024) and heterogeneity (I2 = 87.1%, p < 0.001). However, when analysis was restricted to high quality cohort studies, the association remained significantly (HR, 1.36; 95%CI 1.11-1.68; p = 0.004), with no evidence of publication bias (p = 0.192) and heterogeneity (I2 = 23.2%, p = 0.245).Conclusions Diabetes is associated with increased risk of VTE, which may have implications for the primary and secondary prevention of VTE.
    Thrombosis Research 11/2014; · 2.43 Impact Factor

Full-text (2 Sources)

Download
3 Downloads
Available from
Dec 28, 2014